A thrombolytic liquid preparation capable of avoiding fibrinogen degradation and a preparation method thereof

A protein source and liquid embolization technology, applied in the field of medicine, can solve problems such as bleeding, and achieve the effects of good repeatability, reduced bleeding risk rate, and stable quality

Inactive Publication Date: 2013-10-02
SHANGHAI OCEAN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] One of the objectives of the present invention is to overcome the above-mentioned deficiency that the existing thrombolytic drugs degrade the fibrinogen in the blood and cause severe adverse reactions such as bleeding, and provide a thrombolytic liquid preparation that avoids the degradation of fibrinogen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A thrombolytic liquid preparation capable of avoiding fibrinogen degradation and a preparation method thereof
  • A thrombolytic liquid preparation capable of avoiding fibrinogen degradation and a preparation method thereof
  • A thrombolytic liquid preparation capable of avoiding fibrinogen degradation and a preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Experimental materials: 30 Wistar rats, FGFC1 50mg, sodium bicarbonate 50mg, 0.85% normal saline

[0039]The specific operation of the experiment is as follows: (1) Solution preparation: Weigh FGFC1, then weigh an equivalent amount of co-solvent sodium bicarbonate, add 10ml of normal saline to stir and dissolve, so that the concentration of FGFC1 in the final prepared solution is 5.0mg / ml; ( 2) Filtration: Filter and sterilize the prepared solution with a 0.2 μm microporous membrane, measure the content of FGFC1 in the solution again, put it into a brown bottle after passing the test, and avoid light. (3) Intravenous injection: Wipe the tail of the rat with alcohol cotton to dilate the vein for injection, and then inject through the tail vein according to the ratio of 2ml / 20g. The injection speed is slow to avoid the death of the rat due to heart failure. (4) Blood collection: sacrificed and dissected at 30 minutes and 2 hours respectively, blood was collected from the ...

Embodiment 2

[0041] Experimental materials: 30 Wistar rats, FGFC1 10mg, sodium bicarbonate 10mg, 0.85% normal saline

[0042] The specific operation of the experiment is as follows: (1) Solution preparation: weigh FGFC1, then weigh an equivalent amount of co-solvent sodium bicarbonate, add 4ml of normal saline to stir and dissolve, so that the concentration of FGFC1 in the final prepared solution is 2.5mg / ml; ( 2) Filtration: Filter and sterilize the prepared solution with a 0.2 μm microporous membrane, measure the content of FGFC1 in the solution again, put it into a brown bottle after passing the test, and avoid light. (3) Intravenous injection: Wipe the tail of the rat with alcohol cotton to dilate the vein for injection, and then inject through the tail vein according to the ratio of 2ml / 20g. The injection speed is slow to avoid the death of the rat due to heart failure. (4) Blood collection: sacrificed and dissected at 30 minutes and 2 hours respectively, blood was collected from the ...

Embodiment 3

[0044] Experimental materials: 30 Wistar rats, FGFC1 10mg, sodium bicarbonate 10mg, 0.85% normal saline

[0045] The specific operation of the experiment is as follows: (1) Solution preparation: weigh FGFC1, then weigh an equivalent amount of co-solvent sodium bicarbonate, add 10ml of normal saline to stir and dissolve, so that the concentration of FGFC1 in the final prepared solution is 1.0mg / ml; ( 2) Filtration: Filter and sterilize the prepared solution with a 0.2 μm microporous membrane, measure the content of FGFC1 in the solution again, put it into a brown bottle after passing the test, and avoid light. (3) Intravenous injection: Wipe the tail of the rat with alcohol cotton to dilate the vein for injection, and then inject through the tail vein according to the ratio of 2ml / 20g. The injection speed is slow to avoid the death of the rat due to heart failure. (4) Blood collection: sacrificed and dissected at 30 minutes and 2 hours respectively, blood was collected from the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a thrombolytic liquid preparation capable of avoiding fibrinogen degradation. The thrombolytic liquid preparation is characterized in that the thrombolytic liquid preparation is prepared from FGFCI powder, a cosolvent and normal saline, wherein the concentration of the FGFCI in the thrombolytic liquid preparation is 1-5 mg/mL. The thrombolytic liquid preparation provided by the invention has advantages, in a concentration range in which thromboclasis can be performed, comprising good repeatability and quality stabilization. In addition, in-vitro Caco-2 experiments show that a proper administration route for the FGFCI is intravenous injection which fully meets the needs of clinical medication, and reduction of bleeding risk and achievement of good thrombolytic effects.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a thrombus-dissolving liquid preparation for avoiding fibrinogen degradation and a preparation method thereof. Background technique [0002] Thrombus refers to the clot formed by blood components (coagulation factors, platelets, fibrinogen) in the human body in the blood vessel or heart, and embolism refers to the complete or partial loss of the thrombus formed in the heart or blood vessel, which is blocked with the blood flow to the far end Vascular lumen. Thrombotic diseases such as thrombosis and embolism are one of the diseases that seriously endanger human health. It involves diseases of the blood and circulatory system, and its morbidity and mortality are high. In recent years, with the in-depth research on thrombosis, finding and developing antithrombotic drugs with good effect and less side effects is the core content in the field of cardiovascular and cerebrovascular d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/407A61K47/04A61K9/08A61P7/02
Inventor 吴文惠严婷苏同伟孔婷陈佳捷包斌朱全刚朱玉平
Owner SHANGHAI OCEAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap